Zacks Research Analysts Increase Earnings Estimates for SRPT

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research raised their FY2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $2.02 for the year, up from their prior estimate of $1.78. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Several other equities analysts have also recently issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Trading Up 4.3 %

NASDAQ:SRPT opened at $119.02 on Wednesday. The stock has a market cap of $11.37 billion, a price-to-earnings ratio of 95.22 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company’s 50 day moving average price is $122.07 and its 200-day moving average price is $126.45. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Manchester Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. grew its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics during the fourth quarter worth $36,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.